Prentiss Smith & CO Inc Glycomimetics Inc Transaction History

Prentiss Smith & CO Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 31, 2023	BUY	$0.57 - $3.03 $638 - $3,393	1,120 Added 8.0%	15,120 $45,000
Q4 2020 Feb 03, 2021	BUY	$2.69 - $4.24 $37,660 - $59,360	14,000 New	14,000 $53,000
Q4 2019 Jan 21, 2020	SELL	$4.03 - $6.5 $68,510 - $110,500	-17,000 Closed	0 $0
Q3 2019 Nov 06, 2019	BUY	$2.8 - $12.85 $47,600 - $218,450	17,000 New	17,000 $73,000
Q1 2019 Jul 01, 2019	SELL	$9.96 - $13.44 $99,600 - $134,400	-10,000 Closed	0 $0
Q4 2018 Jan 15, 2019	BUY	$8.47 - $14.71 $25,410 - $44,130	3,000 Added 42.86%	10,000 $95,000
Q4 2017 Feb 13, 2018	SELL	$10.51 - $17.22 $31,530 - $51,660	-3,000 Reduced 30.0%	7,000 $118,000
Q3 2017 Oct 23, 2017	BUY	$10.14 - $14.85 $101,400 - $148,500	10,000	10,000 $140,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Prentiss Smith & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Prentiss Smith & CO Inc with notifications on news.